1308814-98-3

Basic information

• Product Name: ethyl 1-(4-nitrophenyl)cyclopropanecarboxylate
• Synonyms: ethyl 1-(4-nitrophenyl)cyclopropanecarboxylate
• CAS NO: 1308814-98-3
• Molecular Weight: 0
• Mol File: 1308814-98-3.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: ethyl 1-(4-nitrophenyl)cyclopropanecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 1-(4-nitrophenyl)cyclopropanecarboxylate(1308814-98-3)
• EPA Substance Registry System: ethyl 1-(4-nitrophenyl)cyclopropanecarboxylate(1308814-98-3)

Safety Data

• Hazardous Substances Data: 1308814-98-3(Hazardous Substances Data)

Upstream product

• 104-03-0 4-nitrobenzeneacetic acid 
• 5445-26-1 ETHYL 4-NITROPHENYLACETATE 
• 106-93-4 ethylene dibromide 
• 935-44-4 1-cyano-1-phenylcyclopropane 
• 64-17-5 ethanol 
• 408328-42-7 1-(4-nitrophenyl)-1-cyclopropylcarbonitrile 
• 67-56-1 methanol 
• 23348-99-4 1-(4-nitrophenyl)cyclopropane-1-carboxylic acid 
• 6120-95-2 1-phenyl-1-cyclopropane carboxylic acid 

Downstream Products

• 1308815-00-0 ethyl 1-(4-((3-(1,3-dioxoisoindolin-2-yl)-2-hydroxypropyl)amino)phenyl)cyclopropanecarboxylate 
• 1308815-10-2 ethyl 1-(4-(((benzyloxy)carbonyl)amino)phenyl)cyclopropanecarboxylate 

Relevant articles and documents

Immunomodulator

The invention discloses an immunomodulator, and particularly relates to a compound for inhibiting IL-17A and application of the compound serving as the immunomodulator in preparation of drugs. The invention discloses application of a compound shown in a formula I or a stereoisomer thereof in preparation of medicines for inhibiting IL-17A, and provides a new choice for clinically screening and/or preparing medicines for treating diseases related to IL-17A activity.

COMPOUNDS AND METHODS FOR INHIBITING CYP26 ENZYMES

Compounds described herein are inhibitors of retinoic acid inducible P450 (CYP26) enzymes, and are useful for treating diseases that are responsive to retinoids. Certain compounds have retinoid activity, are resistant to CYP26-mediated catabolism, and are used for treating diseases that are responsive to retinoids.

QUINAZOLINE DERIVATIVES

Novel quinazolinamide derivatives of the formula (I), in which R1-R4 and X have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.